Mvabea Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to recurrent ebola outbreaks in endemic regions, global emergency response initiatives, early adoption of mva-based vaccine platforms, involvement of international health organizations, expansion of humanitarian vaccination campaigns.

The growth in the forecast period can be attributed to increasing focus on pandemic preparedness, rising funding for emerging infectious disease vaccines, expansion of stockpiling strategies, growing use of vector-based vaccine technologies, increased global health security investments. Major trends in the forecast period include increasing deployment of ebola vaccination programs, rising focus on outbreak preparedness, expansion of two-dose vaccine regimens, growing investment in viral vector platforms, enhanced international collaboration for disease control.

The increasing incidence of Ebola is expected to drive the growth of the Mvabea market in the future. Ebola is a highly contagious and often fatal disease caused by the Ebola virus, which belongs to the filovirus family. The rise in Ebola cases can be attributed to factors such as increased human-wildlife interactions, urbanization, weakened healthcare systems, and difficulties in rapid disease detection and response. MVABE (Monoclonal Vaccine Against Ebola) plays a crucial role in combating Ebola by providing targeted immunity through antibodies that specifically bind to and neutralize the Ebola virus, helping to prevent infection or reduce the severity of the disease in individuals exposed to the virus. For instance, in April 2025, the World Health Organization (WHO) reported that Uganda had declared the end of a Sudan virus disease outbreak that began on January 30, 2025, with 14 cases and 4 deaths, compared to the 164 cases and 77 deaths in the previous Sudan-strain Ebola outbreak in 2022. Therefore, the rising incidence of Ebola is contributing to the growth of the Mvabea market.

A significant trend in the MVA-BN market is the regulatory approval for its mpox vaccine, Imvanex (MVA-BN), for use in adolescents aged 12 to 17 years. Regulatory approvals are formal authorizations granted by governmental or regulatory bodies that allow a drug, medical device, or treatment to be marketed and used by the public. For example, in September 2024, Bavarian Nordic, a Denmark-based biotechnology company, received FDA approval and EMA authorization for its mpox vaccine targeting the 12-17 age group. The MVA-BN vaccine, marketed under JYNNEOS, IMVAMUNE, and IMVANEX, is a non-replicating live virus vaccine suitable for immunocompromised individuals. It is approved for the prevention of both mpox and smallpox, with approximately 76% effectiveness with a single dose and over 80% with two doses. It is authorized for adults aged 18 and older, with emergency use granted for high-risk adolescents aged 12 to 17. The vaccine can be stored for up to eight weeks at 2-8 degrees Celsius and has a favorable safety profile with mild to moderate side effects.

In July 2025, Innosera ApS, a Sweden/UK-based consortium led by private equity managers Nordic Capital (Sweden) and Permira (UK), acquired Bavarian Nordic A/S for around DKK 19 billion (~US$2.8-3.1 billion) in an all-cash offer. This acquisition aims to take Bavarian Nordic private to accelerate strategic investments in vaccine manufacturing, expand global supply capabilities, and pursue long-term value creation free from the pressures of the public market. Bavarian Nordic A/S is a Denmark-based company specializing in vaccine development and manufacturing, including vaccines for smallpox/monkeypox and components relevant to Mvabea.

Major companies operating in the mvabea market are Johnson & Johnson.

North America was the largest region in the mvabea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mvabea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mvabea market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the mvabea market by increasing costs of imported viral vector materials, bioprocessing equipment, sterile packaging components, and temperature-controlled logistics required for outbreak-response vaccines. Government-led vaccination programs in Africa, Europe, and North America are most affected due to reliance on internationally manufactured vaccine components and transport systems. These tariffs are raising procurement and deployment costs during emergency response efforts. However, they are also encouraging regional vaccine manufacturing partnerships, localized fill-and-finish facilities, and capacity building in endemic regions to improve long-term vaccine accessibility.

The mvabea market research report is one of a series of new reports that provides mvabea market statistics, including mvabea industry global market size, regional shares, competitors with a mvabea market share, detailed mvabea market segments, market trends and opportunities, and any further data you may need to thrive in the mvabea industry. This mvabea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mvabea is part of a two-dose Ebola vaccine regimen developed to protect against the Zaire Ebola virus species. It works in conjunction with Zabdeno (Ad26.ZEBOV) and is administered as the second dose to enhance the immune response. Mvabea utilizes a modified vaccinia Ankara (MVA) vector to deliver viral proteins and stimulate immunity.

The primary product types of Mvabea include Mvabea (MVA-BN-Filo) and Zabdeno (Ad26.ZEBOV). Mvabea is specifically designed to protect against Ebola virus disease caused by the Zaire ebolavirus. Its applications include the prevention of Ebola virus disease and outbreak control efforts. Mvabea is utilized by various end users, including government agencies, healthcare providers, and research institutions.

The mvabea market consists of sales of ebola vaccine regimens in combination with Zabdeno (Ad26.ZEBOV). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.